Ileal bile acid transporter inhibitors

Pediatric cholestatic liver diseases, such as Alagille syndrome and progressive familial intrahepatic cholestasis, are rare genetic disorders characterized by impaired bile flow, systemic bile acid accumulation, and debilitating pruritus. Historically managed with supportive care or invasive surgical interventions, the therapeutic landscape has recently expanded with the introduction of ileal bile acid transporter (IBAT) inhibitors. These luminal, ileum-targeted agents block bile acid reabsorption, thereby increasing fecal bile acid excretion and effectively reducing the systemic bile acid pool to relieve pruritus. However, this pharmacological blockade also attenuates the intestinal farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) feedback loop, leading to a compensatory increase in hepatic bile acid synthesis. Consequently, the clinical efficacy and safety of IBAT inhibitors are heavily dependent on a sufficiently preserved enterohepatic bile flow and canalicular export capacity. When luminal bile acid delivery is impaired, therapeutic benefits diminish, and the unchecked compensatory synthesis may contribute to hepatocyte stress and elevated transaminases. Thus, optimizing the use of these therapies will require a shift from broad disease-label indications toward precision, genotype- and physiology-informed patient selection, utilizing non-invasive biomarkers to assess target engagement and guide clinical management.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-17
DOI
https://doi.org/10.1002/jpn3.70692
Primary Topic
Pediatric Hepatobiliary Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ileal bile acid transporter inhibitors

Antonio Moschetta, Ersilia Di Buduo, Lucilla Crudele, Silviya Cantatore
3 links
Journal of Pediatric Gastroenterology and Nutrition
Pediatric Hepatobiliary Diseases and Treatments
article

Ileal bile acid transporter inhibitors

Antonio Moschetta, Ersilia Di Buduo, Lucilla Crudele, Silviya Cantatore
article en

Abstract

Pediatric cholestatic liver diseases, such as Alagille syndrome and progressive familial intrahepatic cholestasis, are rare genetic disorders characterized by impaired bile flow, systemic bile acid accumulation, and debilitating pruritus. Historically managed with supportive care or invasive surgical interventions, the therapeutic landscape has recently expanded with the introduction of ileal bile acid transporter (IBAT) inhibitors. These luminal, ileum-targeted agents block bile acid reabsorption, thereby increasing fecal bile acid excretion and effectively reducing the systemic bile acid pool to relieve pruritus. However, this pharmacological blockade also attenuates the intestinal farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) feedback loop, leading to a compensatory increase in hepatic bile acid synthesis. Consequently, the clinical efficacy and safety of IBAT inhibitors are heavily dependent on a sufficiently preserved enterohepatic bile flow and canalicular export capacity. When luminal bile acid delivery is impaired, therapeutic benefits diminish, and the unchecked compensatory synthesis may contribute to hepatocyte stress and elevated transaminases. Thus, optimizing the use of these therapies will require a shift from broad disease-label indications toward precision, genotype- and physiology-informed patient selection, utilizing non-invasive biomarkers to assess target engagement and guide clinical management.

Journal of Pediatric Gastroenterology and Nutrition
Istituto Nazionale Biostrutture e Biosistemi (IT), University of Bari Aldo Moro (IT)
European Commission, Ministero della Salute
Good health and well-being
Pediatric Hepatobiliary Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon